IONS insider filing: 11,130 shares planned sale via Stifel on 09/02/2025

Rhea-AI Filing Summary

Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 11,130 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $552,865.00. The filing lists 159,391,229 shares outstanding and an approximate sale date of 09/02/2025 on Nasdaq. The securities were acquired as Restricted Stock Units on 01/15/2021 (listed amount acquired: 23,976) and a payment date of 01/15/2017 with Cash noted under payment. No securities were reported sold in the past three months, and the filer attests they are unaware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider disposal; size immaterial relative to outstanding shares.

The filing documents a proposed sale of 11,130 shares valued at $552,865, representing roughly 0.007% of the 159.4 million shares outstanding, indicating a small, routine partial disposition rather than a large, market-moving sale. The use of a broker (Stifel) and the absence of sales in the prior three months are consistent with orderly compliance under Rule 144. Disclosure of acquisition as Restricted Stock Units on 01/15/2021 provides provenance of the holdings. Overall, the notice appears procedural and unlikely to materially affect market valuation.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 procedural requirements; no red flags in disclosures.

The document includes required representations about material nonpublic information and indicates the filer signed the attestation. Broker and planned sale date are specified, satisfying common compliance expectations. One data inconsistency to note is the listed payment date of 01/15/2017 for securities acquired by RSUs on 01/15/2021; the form itself does not explain this, so it should be considered a clerical item unless further clarified by the filer. Absent additional context, the disclosure looks routine from a governance standpoint.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	11130	552865.00	159391229	09/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2021	Restricted Stock Units	Issuer			23976	01/15/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 (IONS) report?

The filing reports a proposed sale of 11,130 shares of common stock with an aggregate market value of $552,865.00, to be sold via Stifel Nicolaus & Company on or about 09/02/2025.

How many Ionis shares are outstanding according to the filing?

The filing lists 159,391,229 shares outstanding.

When and how were the securities being sold acquired?

The securities were acquired as Restricted Stock Units on 01/15/2021, with an indicated acquired amount of 23,976 units and Cash listed under payment.

Did the filer sell any Ionis securities in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale for IONS?

The broker listed is Stifel Nicolaus & Company Inc, address 501 N Broadway, St. Louis, MO; the securities exchange is Nasdaq.